These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 21846426)

  • 1. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.
    Mitchell AJ; Delaffon V; Vancampfort D; Correll CU; De Hert M
    Psychol Med; 2012 Jan; 42(1):125-47. PubMed ID: 21846426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions to Improve Metabolic Risk Screening Among Adult Patients Taking Antipsychotic Medication: A Systematic Review.
    Melamed OC; Wong EN; LaChance LR; Kanji S; Taylor VH
    Psychiatr Serv; 2019 Dec; 70(12):1138-1156. PubMed ID: 31522630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011.
    Connolly JG; Toomey TJ; Schneeweiss MC
    Psychiatr Serv; 2015 Jun; 66(6):604-9. PubMed ID: 25726977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of treatment guidelines for specialist mental health care.
    Barbui C; Girlanda F; Ay E; Cipriani A; Becker T; Koesters M
    Cochrane Database Syst Rev; 2014 Jan; (1):CD009780. PubMed ID: 24443146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic screening in primary care for patients with schizophrenia or schizoaffective disorder and taking antipsychotic medication.
    Keenan R; Chepulis L; Ly J; Carter S; Lao C; Asim M; Bhat A; Deo S; Lim KP; Mohammed R; Scarlet S; Lawrenson R
    J Prim Health Care; 2020 Mar; 12(1):29-34. PubMed ID: 32223847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation.
    De Hert M; Vancampfort D; Correll CU; Mercken V; Peuskens J; Sweers K; van Winkel R; Mitchell AJ
    Br J Psychiatry; 2011 Aug; 199(2):99-105. PubMed ID: 21804146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration.
    Shi L; Ascher-Svanum H; Chiang YJ; Zhao Y; Fonseca V; Winstead D
    BMC Psychiatry; 2009 Dec; 9():80. PubMed ID: 20021664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of metabolic side-effects in children and adolescents prescribed antipsychotic medication: A systematic review.
    Mead L; Ayres A; Blake JA; Scott JG
    Aust N Z J Psychiatry; 2021 Aug; 55(8):763-771. PubMed ID: 33951933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of a computerized best practice alert system in an outpatient setting on metabolic monitoring in patients on second-generation antipsychotics.
    Cohen S; Bostwick JR; Marshall VD; Kruse K; Dalack GW; Patel P
    J Clin Pharm Ther; 2020 Dec; 45(6):1398-1404. PubMed ID: 32767599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation of treatment guidelines for specialist mental health care.
    Bighelli I; Ostuzzi G; Girlanda F; Cipriani A; Becker T; Koesters M; Barbui C
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD009780. PubMed ID: 27977851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interventions for preventing type 2 diabetes in adults with mental disorders in low- and middle-income countries.
    Mishu MP; Uphoff E; Aslam F; Philip S; Wright J; Tirbhowan N; Ajjan RA; Al Azdi Z; Stubbs B; Churchill R; Siddiqi N
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD013281. PubMed ID: 33591592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study - a cross-sectional study.
    Fontaine J; Chin E; Provencher JF; Rainone A; Wazzan D; Roy C; Rej S; Lordkipanidze M; Dagenais-Beaulé V
    BMJ Open; 2022 Apr; 12(4):e055454. PubMed ID: 35414553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventions to Improve Metabolic Risk Screening Among Children and Adolescents on Antipsychotic Medication: A Systematic Review.
    Melamed OC; LaChance LR; O'Neill BG; Rodak T; Taylor VH
    J Child Adolesc Psychopharmacol; 2021 Feb; 31(1):63-72. PubMed ID: 33512274
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of cardiovascular disease risk in patients with schizophrenia spectrum disorders in German psychiatric hospitals: results of the pharmacoepidemiologic CATS study.
    Deuschle M; Paul F; Brosz M; Bergemann N; Franz M; Kammerer-Ciernioch J; Lautenschlager M; Lederbogen F; Roesch-Ely D; Weisbrod M; Kahl KG; Reichmann J; Gross J; Umbreit J
    Soc Psychiatry Psychiatr Epidemiol; 2013 Aug; 48(8):1283-8. PubMed ID: 23515714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic grand rounds: economic costs of failure to monitor adverse effects of second-generation antipsychotics: an underestimated factor.
    Jerrell JM; McIntyre RS; Black GB
    Psychiatr Serv; 2012 Mar; 63(3):202-4. PubMed ID: 22388526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.
    Morrato EH; Druss B; Hartung DM; Valuck RJ; Allen R; Campagna E; Newcomer JW
    Arch Gen Psychiatry; 2010 Jan; 67(1):17-24. PubMed ID: 20048219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
    De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
    CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistence of metabolic monitoring for psychiatry inpatients treated with second-generation antipsychotics utilizing a computer-based intervention.
    Lee J; Dalack GW; Casher MI; Eappen SA; Bostwick JR
    J Clin Pharm Ther; 2016 Apr; 41(2):209-13. PubMed ID: 26919449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.
    Citrome L; Holt RI; Walker DJ; Hoffmann VP
    Clin Drug Investig; 2011; 31(7):455-82. PubMed ID: 21495734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.